康哲药业：2026年7月获创新药CMS-D017 AMD适应症临床试验批件

智通财经07-15 18:37

【康哲药业：2026年7月获创新药CMS-D017 AMD适应症临床试验批件】康哲药业公告，公司自主研发的创新药补体因子B抑制剂CMS-D017胶囊于2026年7月15日获得中国国家药品监督管理局签发的药物临床试验批准通知书，同意开展治疗年龄相关性黄斑变性适应症的临床试验。此前，CMS-D017已分别于2026年1月30日及2月3日获得关于阵发性睡眠性血红蛋白尿症与补体参与介导的肾脏疾病适应症的临床试验批准通知书。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2651528874?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-15 18:37","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2651528874","market":"us","top_or_hot":-1,"title":"康哲药业：2026年7月获创新药CMS-D017 AMD适应症临床试验批件","media":"智通财经","content":"<html><body><div>\n<div>\n<b>【康哲药业：2026年7月获创新药CMS-D017 AMD适应症临床试验批件】</b>康哲药业公告，公司自主研发的创新药补体因子B抑制剂CMS-D017胶囊于2026年7月15日获得中国国家药品监督管理局签发的药物临床试验批准通知书，同意开展治疗年龄相关性黄斑变性适应症的临床试验。此前，CMS-D017已分别于2026年1月30日及2月3日获得关于阵发性睡眠性血红蛋白尿症与补体参与介导的肾脏疾病适应症的临床试验批准通知书。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康哲药业：2026年7月获创新药CMS-D017 AMD适应症临床试验批件</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康哲药业：2026年7月获创新药CMS-D017 AMD适应症临床试验批件\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【康哲药业：2026年7月获创新药CMS-D017 AMD适应症临床试验批件】</b>康哲药业公告，公司自主研发的创新药补体因子B抑制剂CMS-D017胶囊于2026年7月15日获得中国国家药品监督管理局签发的药物临床试验批准通知书，同意开展治疗年龄相关性黄斑变性适应症的临床试验。此前，CMS-D017已分别于2026年1月30日及2月3日获得关于阵发性睡眠性血红蛋白尿症与补体参与介导的肾脏疾病适应症的临床试验批准通知书。                </div>\n</div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMDG","symbol_name":"2倍做多AMD ETF- Leverage Shares","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2651528874","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651528874","pubTimestamp":1784111824,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【康哲药业：2026年7月获创新药CMS-D017 AMD适应症临床试验批件】康哲药业公告，公司自主研发的创新药补体因子B抑制剂CMS-D017胶囊于2026年7月15日获得中国国家药品监督管理局签发","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"AMDG":"2倍做多AMD ETF- Leverage Shares","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","IETC":"iShares U.S. Tech Independence Focused ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","ARTY":"ISHARES FUTURE AI & TECH ETF","SMHX":"VanEck Fabless Semiconductor ETF","AMDL":"2倍做多AMD ETF-GraniteShares","USXF":"iShares ESG Advanced MSCI USA ETF","BK4566":"资本集团","CMS":"CMS能源","TEK":"iShares Technology Opportunities Active ETF","AMD":"美国超微公司","FTXL":"First Trust Nasdaq Semiconductor ETF","CHPS":"XTRACKERS SEMICONDUCTOR SELECT EQUITY ETF","BAI":"iShares A.I. Innovation and Tech Active ETF","GFS":"GLOBALFOUNDRIES Inc.","AMDS":"GRANITESHARES 1X SHORT AMD DAILY ETF","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","XNTK":"SPDR NYSE Technology ETF","AIS":"VistaShares Artificial Intelligence Supercycle ETF","SMH":"半导体指数ETF-HOLDRs","AMDU":"Defiance Leveraged Long + Income AMD ETF","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","AMUU":"2倍做多AMD ETF-Direxion","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","AMDW":"Roundhill AMD WeeklyPay ETF","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","CNAV":"Mohr Company Nav ETF","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","TTEQ":"T. Rowe Price Technology ETF","AMDY":"AMD期权收益策略ETF-YieldMax","PSI":"INVESCO SEMICONDUCTORS ETF","FAI":"First Trust Bloomberg Artificial Intelligence ETF","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","AMYY":"GraniteShares YieldBOOST AMD ETF","WUGI":"AXS Esoterica NextG Economy ETF","MEDX":"HORIZON KINETICS MEDICAL ETF","SOXX":"iShares费城交易所半导体ETF","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","DAMD":"2倍做空AMD ETF-Defiance","ILDR":"First Trust Innovation Leaders ETF","SOXY":"YieldMax Target 12 Semiconductor Option Income ETF","TRFK":"PACER DATA AND DIGITAL REVOLUTION ETF","BMED":"iShares Health Innovation Active ETF","WISE":"THEMES GENERATIVE ARTIFICIAL INTELLIGENCE ETF","LEGR":"First Trust Indxx Innovative Transaction & Process ETF","AIQ":"Global X Artificial Intelligence & Technology ETF","AMDD":"1倍做空AMD ETF-Direxion","QQQA":"ProShares Nasdaq-100 Dorsey Wright Momentum ETF"},"translate_title":"Kangzhe Pharmaceutical: Obtained clinical trial approval for innovative drug CMS-D017 AMD indication in July 2026","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/7b4066e250b2db8248945b06650be40d","symbols_score_info":{"AMD":1.5,"CHAT":0.6,"BMED":1.5,"AMDW":0.6,"AMUU":0.6,"MEDX":1.5,"SMHX":0.6,"CMS":1.5,"GFS":1.5,"QQQA":0.6,"SMH":0.6,"FTXL":0.6,"WUGI":0.6,"AMDL":0.6,"AMDU":0.6,"XNTK":0.6,"PSI":0.6,"TEK":0.6,"AMDD":0.6,"CHPS":0.6,"TRFK":0.6,"AIS":0.6,"USXF":0.6,"TTEQ":0.6,"WISE":0.6,"IBBQ":1.5,"SOXX":0.6,"ILDR":0.6,"AMDG":0.6,"DAMD":0.6,"SOXY":0.6,"CNAV":0.6,"ARTY":0.6,"BAI":0.6,"AMYY":0.6,"LEGR":0.6,"AIQ":0.6,"IETC":0.6,"AMDY":0.6,"AMDS":0.6,"FAI":0.6},"content_text":"【康哲药业：2026年7月获创新药CMS-D017 AMD适应症临床试验批件】康哲药业公告，公司自主研发的创新药补体因子B抑制剂CMS-D017胶囊于2026年7月15日获得中国国家药品监督管理局签发的药物临床试验批准通知书，同意开展治疗年龄相关性黄斑变性适应症的临床试验。此前，CMS-D017已分别于2026年1月30日及2月3日获得关于阵发性睡眠性血红蛋白尿症与补体参与介导的肾脏疾病适应症的临床试验批准通知书。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651528874","isCrawlerRequest":true}